Indications

• venous thromboembolism ^a
• atrial fibrillation ^a
• heart valves ^a
• anti-phospholipid syndrome ^c
  

• Pulmonary embolism: anticoagulation reduces death and recurrent PE. ^a

Pulmonary embolism: anticoagulation reduces recurrent and fatal pulmonary embolism

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
pulmonary embolism a	warfarin	placebo	death from PE at 12 months	26%	100%	4 (2 to 15)
			recurrent PE at 12 months	32%	100%	3 (2 to 9)

• Atrial fibrillation: anticoagulation reduces death and strokes ^a

Atrial fibrillation: anticoagulation reduces death and stroke

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
atrial fibrillation a	warfarin	placebo	stroke at 1-2 years	6.6%	66% (48% to 78%)	23 (17 to 36)
			death at 1-2 years	8.0%	30% (5% to 48%)	42 (23 to 260)

• Mechanical heart valves: warfarin reduces embolic events. ^c
• Anti-phospholipid syndrome: warfarin reduces recurrent thrombosis ^c

Anti-phospholipid syndrome: anticoagulation reduces recurrent thrombosis

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
anti-phospholipid syndrome c	warfarin	nothing	recurrent thrombosis at 10 years	48%	90% (70% to 97%)	2 (2 to 3)